[EN] How to Better Optimize an Oncology Drug Discovery Program

Watch this webinar

Progress has been made in a deeper understanding of the molecular mechanisms of cancer and in the development of innovative therapeutic agents. However, the attrition rates between target discovery and drug approval remain very high. Therefore, robust translational assays and models to predict therapeutic efficiencies have become a key parameter for oncology drug discovery programs.

Experienced, multidisciplinary teams and strategic partnerships can support drug discovery projects from hit finding to Investigational New Drug (IND).

Key learning objectives

In this webinar, the featured speakers will discuss how conventional and innovative integrated technological skills should be incorporated into the oncology drug discovery process. This effort should help the selection of drug candidates faster to the clinic. The webinar will use examples of anticancer drugs aimed at overcoming breast cancer resistance by following a multiple-step program which includes:

  • Target expression/validation to identify the most effective therapeutic strategies
  • In vitro screening and phenotypic assays, to select active compounds, confirm activity and better understand the mechanism of action
  • Early absorption, distribution, metabolism and excretion (ADME), to establish developability potential of entities
  • In vivo validation to evaluate the dose effect and therapeutic index of the compounds
  • In vivo clinical drug positioning

About our speakers

Jean-François Mirjolet, Head of In Vitro Sciences, Oncodesign

Jean-François Mirjolet is the head of the In Vitro Sciences Department at Oncodesign BU Service. He has been working for Oncodesign for 17 years, going through various positions from study director, technology director to his current role, managing both services and R&D related in vitro activities.

He obtained his PhD from the University of Nancy (France) in cellular pharmacology of anticancer drugs, followed by post-doctoral position at the IRIBHM, Brussels (Belgium) in chemokines and chemokine receptors implication in cancer cell migration.

Olivier Duchamp, Head of In Vivo Sciences, Oncodesign

Olivier Duchamp is the head of the In Vivo Sciences Department at Oncodesign BU Service. He was at the founding of the company and for the last 26 years, contributed largely to its development and innovation in preclinical models and pharmaco-imaging. He holds a bachelor’s degree from the University of Lyon (France) and a master’s degree in pharmacology and analytical methods from the University of Paris IV (France).

Olivier is also the coordinator of IMODI, (Innovative MODels Initiative), a French consortium dedicated to the development, the characterization and the commercialization of new preclinical models in oncology, including PDX models and humanized mouse models. He is the co-author of several publications about PDX models.

Watch this webinar